Results 21 to 30 of about 94,921 (285)

Myofibroblasts and Transforming Growth Factor-Beta1 in Reactive Gingival Overgrowths

open access: yeseJournal of Oral Maxillofacial Research, 2013
Objectives: The aim of this study was to detect the presence of myofibroblasts and transforming growth factor-beta1 in fibrous and ossifying-fibrous epulis and their possible contribution to the collagenous connective tissue formation.
Apostolos Epivatianos   +2 more
doaj   +1 more source

Novel Therapies for the Treatment of Cardiac Fibrosis Following Myocardial Infarction

open access: yesBiomedicines, 2022
Cardiac fibrosis is a common pathological consequence of most myocardial diseases. It is associated with the excessive accumulation of extracellular matrix proteins as well as fibroblast differentiation into myofibroblasts in the cardiac interstitium ...
Kamila Raziyeva   +4 more
doaj   +1 more source

Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality? [PDF]

open access: yes, 2016
Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by progressive fibrosis of skin and multiple internal organs and severe functional and structural microvascular alterations.
Jimenez, Sergio A.   +1 more
core   +2 more sources

Progenitor cells, bone marrow–derived fibrocytes and endothelial-to-mesenchymal transition: new players in vascular fibrosis [PDF]

open access: yes, 2016
No abstract ...
Harvey, Adam   +4 more
core   +2 more sources

Hepatic stellate cells and parasite-induced liver fibrosis [PDF]

open access: yes, 2010
: Fibrogenesis is a common feature of many diseases where there is severe insult to the liver. The hepatic stellate cell trans-differentiation into a myofibroblast has been identified as an important event in liver fibrogenesis and has been well ...
Allen, JT   +3 more
core   +2 more sources

Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease. [PDF]

open access: yes, 2016
OBJECTIVE: To examine whether lung endothelial cells (ECs) from patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD) express mesenchymal cell-specific proteins and gene transcripts, indicative of the occurrence of endothelial-
Arciniegas   +41 more
core   +2 more sources

Inflammatory Myofibroblastic Tumour

open access: yesEuropean Journal of Case Reports in Internal Medicine, 2020
Inflammatory myofibroblastic tumour (IMT) is a rare mesenchymal tumour. It is usually benign but may behave as a malignant tumour with multiple recurrences and metastases. We present the case of a young woman with weight loss associated with diffuse abdominal pain, who was shown to have a large pancreatic mass.
Pimentel Duarte, Pedro   +4 more
openaire   +3 more sources

Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy [PDF]

open access: yes, 2018
Background: Fibrosis may be considered the hallmark of systemic sclerosis (SSc), the end stage triggered by different pathological events. Transforming growth factor-β (TGF-β) and platelet-derived growth factor BB (PDGF-BB) are profibrotic molecules ...
Berardicurti O.   +11 more
core   +1 more source

Myofibroblast dedifferentiation proceeds via distinct transcriptomic and phenotypic transitions

open access: yesJCI Insight, 2021
Myofibroblasts are the major cellular source of collagen, and their accumulation — via differentiation from fibroblasts and resistance to apoptosis — is a hallmark of tissue fibrosis.
Sean M. Fortier   +5 more
doaj   +1 more source

Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. [PDF]

open access: yes, 2017
BACKGROUND: Gastrointestinal tract (GIT) involvement is a common cause of debilitating symptoms in patients with systemic sclerosis (SSc). There are no disease modifying therapies for this condition and the treatment remains symptomatic, largely owing to
Abraham   +105 more
core   +2 more sources

Home - About - Disclaimer - Privacy